EU/3/12/954

About

On 9 February 2012, orphan designation (EU/3/12/954) was granted by the European Commission to University of Sheffield (SITraN), United Kingdom, for the treatment of amyotrophic lateral sclerosis.

The sponsorship was transferred to Granzer Regulatory Consulting & Services, Germany, in September 2019.

Key facts

Active substance
S[+] apomorphine
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of first decision
09/02/2012
Outcome
Positive
EU designation number
EU/3/12/954

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Granzer Regulatory Consulting & Services
Kistlerhofstrasse 172c 
81379 Munich 
Germany 
Tel. + 49 89 780 689 829
E-mail: info@aclipsetherapeutics.com 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating